DNA today
$9.61-$0.62 (-6.06%)close Nov 13, 2026Trend
DailyUptrend (starting)
4 hourStrong Bearish
1 hourStrong Bearish
15 minSymmetric Triangle
5 minStrong Bullish
Daily trend turns down below $5.00
Key levels
Resistance$13.12
Resistance$11.10
Support$9.28
Support$6.52
Latest news & SEC filings
AnalystTD Cowen lowers its rating on Ginkgo Bioworks
EarningsGinkgo Bioworks posts Q3 2026 results and completes first autonomous lab sale
EarningsGinkgo Bioworks posts smaller quarterly loss than expected, revenue tops forecast
All DNA news →About Ginkgo Bioworks
Ginkgo Bioworks provides biological research and development services through two segments. Its cell engineering business offers tools and lab services that help customers in medicine, agriculture, and industrial biotechnology design and manufacture products. Its biosecurity unit supplies genomic monitoring and analytics to government customers. The company serves clients worldwide.
Based on the company's 10-K filed Feb 26, 2026.
NYSE · Healthcare
Ginkgo Bioworks Holdings, Inc. (DNA)
What Is the Price Target for DNA?
SEPT Low Target
$5.00
SEPT Mid Target
$8.00
SEPT High Target
$11.00
Analyst Consensus
$8.00
Is DNA a Buy or Sell Right Now?
Thesis
- •Revenue growing -25.1% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for DNA.
Start Free Trial →Is DNA Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
Analyst Consensus
Fair Value
$8.00
19
Moat Score
NONE
2/9
Piotroski Score
-7.4
Altman Z-Score
What Is Smart Money Doing with DNA?
Insider Signal
SELLING
0 buys / 8 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Coen Steven P. | officer | Sale | 766 | $8K | Oct 19, 2026 |
| Canton Barry | 10% owner | Sale | 18,803 | $191K | Oct 19, 2026 |
| Canton Barry | 10% owner | Sale | 22,369 | $227K | Oct 19, 2026 |
| Shetty Reshma P. | director officer 10% owner | Sale | 22,369 | $227K | Oct 19, 2026 |
| Shetty Reshma P. | director officer 10% owner | Sale | 18,803 | $191K | Oct 19, 2026 |
| Kelly Jason R | director officer | Sale | 45,682 | $463K | Oct 19, 2026 |
| Coen Steven P. | officer | Buy | 1,174 | - | Oct 16, 2026 |
| Coen Steven P. | officer | Buy | 312 | - | Oct 16, 2026 |
| Canton Barry | 10% owner | Buy | 26,802 | - | Oct 16, 2026 |
| Canton Barry | 10% owner | Buy | 9,762 | - | Oct 16, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →DNA Growth Story
Revenue YoY
-25.1%
3yr Revenue CAGR
-29.1%
EPS Growth YoY
46.49%
FCF Growth YoY
53.2%
Revenue Trend
ACCELERATING
Dark Pool Trades for DNA
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for DNA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 18:05:08 | $9.46 | 8,000 | $$76K | SELL |
| 17:34:49 | $9.55 | 1,600 | $$15K | SELL |
| 17:27:24 | $9.54 | 28,322 | $$270K | BUY |
| 17:13:40 | $9.48 | 1,000 | $$9K | SELL |
| 17:07:34 | $9.46 | 1,106 | $$10K | BUY |
5 dark pool trades shown · $$381K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for DNA
PREVIEWSEPT Investing provides real-time options flow tracking for DNA, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $11 | Nov 20 | 7 | $$2650 | 106 | BLOCK |
| CALL | $11 | Nov 20 | 7 | $$2400 | 96 | SWEEP |
| CALL | $11 | Nov 20 | 7 | $$2700 | 108 | BLOCK |
| CALL | $9 | Nov 20 | 7 | $$665 | 7 | SWEEP |
| CALL | $9 | Nov 20 | 7 | $$665 | 7 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Ginkgo Bioworks Holdings, Inc. (DNA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →DNA — frequently asked questions
What is DNA stock price today?
Ginkgo Bioworks Holdings, Inc. (DNA) is at $9.61, down 6.06% (-$0.62) at the Nov 13, 2026 close.
Why is DNA stock moving today?
Latest DNA news — Nov 7, 2026: TD Cowen lowers its rating on Ginkgo Bioworks · Nov 5, 2026: Ginkgo Bioworks posts Q3 2026 results and completes first autonomous lab sale
What is the DNA price target?
The average analyst price target for DNA is $8.00, ranging from $5 to $11, based on 2 analysts. Latest: TD Cowen maintains on Oct 13, 2026.
What do analysts rate DNA?
Analyst ratings for DNA: 0 Buy, 2 Hold, 1 Sell — consensus Hold.
Did DNA beat earnings?
DNA last reported on Nov 5, 2026: EPS -$0.64 vs -$0.68 expected — a beat of 5.6%.
Does DNA pay a dividend?
DNA does not currently pay a dividend.
What are DNA support and resistance levels?
Support: $9.28, $6.52. Resistance: $11.10, $13.12, $18.22.
What are insiders doing with DNA?
Insider activity: SELLING, 0 buys and 8 sells in the last 90 days.
What is the latest news on DNA?
Nov 7, 2026: TD Cowen lowers its rating on Ginkgo Bioworks · Nov 5, 2026: Ginkgo Bioworks posts Q3 2026 results and completes first autonomous lab sale · Nov 5, 2026: Ginkgo Bioworks posts smaller quarterly loss than expected, revenue tops forecast